Log in

NASDAQ:GERNGeron Stock Price, Forecast & News

$1.54
0.00 (0.00 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.52
Now: $1.54
$1.61
50-Day Range
$1.14
MA: $1.44
$2.06
52-Week Range
$0.75
Now: $1.54
$2.40
Volume2.77 million shs
Average Volume5.01 million shs
Market Capitalization$313.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Read More
Geron logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.68 per share

Profitability

Net Income$-68,550,000.00
Net Margins-16,449.23%

Miscellaneous

Employees45
Market Cap$313.11 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock been impacted by COVID-19 (Coronavirus)?

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GERN stock has increased by 49.5% and is now trading at $1.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Geron?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its quarterly earnings data on Thursday, May, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.04. The biopharmaceutical company earned $0.05 million during the quarter, compared to the consensus estimate of $0.11 million. Geron had a negative net margin of 16,449.23% and a negative return on equity of 52.95%. During the same quarter in the previous year, the business posted ($0.05) earnings per share. View Geron's earnings history.

What price target have analysts set for GERN?

5 brokers have issued 12 month price targets for Geron's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's stock price to reach $3.60 in the next twelve months. This suggests a possible upside of 133.8% from the stock's current price. View analysts' price targets for Geron.

Has Geron been receiving favorable news coverage?

News coverage about GERN stock has trended somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutGeron.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.82%), State Street Corp (1.86%), Geode Capital Management LLC (1.37%), Two Sigma Investments LP (0.80%), Bank of New York Mellon Corp (0.42%) and Two Sigma Advisers LP (0.33%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View institutional ownership trends for Geron.

Which institutional investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, SG Americas Securities LLC, Virtus ETF Advisers LLC, Creative Planning, and Deutsche Bank AG. View insider buying and selling activity for Geron.

Which institutional investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Geode Capital Management LLC, Invesco Ltd., State Street Corp, BlackRock Inc., Advisor Group Holdings Inc., and Commonwealth Equity Services LLC. View insider buying and selling activity for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.54.

How big of a company is Geron?

Geron has a market capitalization of $313.11 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.